Lynk Pharma to Start Trials of Novel Therapy for IBD
June 25, 2021 at 05:06 AM EDT
Hangzhou Lynk Pharma has been OK'd to start clinical trials of a novel Class I drug in patients with inflammatory bowel disease (IBD). LNK01003 is a kinase inhibitor that offers low systemic exposure and high intestinal exposure, lowering potential toxicity caused by immune system suppression. Lynk did not give any details about the candidate's mechanism. LNK01003 is the third Lynk candidate approved for clinical trials. Founded in 2018, Lynk discovers and develops innovative drugs to treat cancer, as well as immune and inflammatory diseases. More details.... Share this with colleagues: // //
